Early Lapatinib-Induced Skin Rash Predicts Better Survival With Lapatinib+Trastuzumab Therapy - Cancer Therapy Advisor
By A Mystery Man Writer
Description
Early development of skin rash following lapatinib and trastuzumab therapy is associated with improved survival.
Efficacy of lapatinib monotherapy on occult breast cancer
Early Adverse Events predict Survival Outcomes in HER2-positive
Resistance and Overcoming Resistance in Breast Cancer - Oncology
Page 1597 – Cancer Therapy Advisor
Lapatinib and lapatinib plus trastuzumab therapy versus
Lapatinib and lapatinib plus trastuzumab therapy versus
Resistance and Overcoming Resistance in Breast Cancer - Oncology
Targeted Molecular Therapy in Head and Neck Squamous Cell
Epidermal growth factor receptor-related signaling pathways and
Lapatinib and lapatinib plus trastuzumab therapy versus
Page 1597 – Cancer Therapy Advisor
Lapatinib with trastuzumab for HER2-positive early breast cancer
from
per adult (price varies by group size)